An effect of the combination of oncolytic adenoviruses and a tyrosine-kinase inhibitor.
Project/Area Number |
16K21639
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Respiratory organ internal medicine
Biological pharmacy
|
Research Institution | Chiba Cancer Center (Research Institute) |
Principal Investigator |
Morinaga Takao 千葉県がんセンター(研究所), がん治療開発グループ, 研究員 (30757000)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 悪性中皮腫 / 遺伝子治療 / アデノウイルス / チロシンキナーゼ / 細胞周期 / adenovirus / wee1 / apoptosis / replication / cell cycle / p53 / Wee1 キナーゼ / 細胞障害活性 / アポトーシス / 癌 / ウイルス / シグナル伝達 |
Outline of Final Research Achievements |
Malignant mesothelioma is an intractable disease; thereby, development of innovative new drugs, which has a non-traditional strategy for cancer treatment is required. We focused on effectiveness of oncolytic adenoviruses on mesothelioma and further explored a drug that can strengthen the antitumor effect of the viruses. Our results suggested that a Wee1 kinase inhibitor could enhance the replication of adenoviruses and augment the cytotoxicity induced by the viruses through the apoptotic pathway.
|
Report
(3 results)
Research Products
(8 results)
-
-
-
[Presentation] A MDM2 inhibitor augments cytotoxicity of oncolytic adenoviruses defective of E1B 55kDa molecules through enhancing DNA damages and apoptosis in mesothelioma2017
Author(s)
Masatoshi Tagawa, Thao Thi Thanh Nguyen, Takao Morinaga, Boya Zhong, Michiko Hanazono, Shuji Kubo, Masato Shingyoji, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima
Organizer
第23回日本遺伝子細胞治療学会学術集会
Related Report
-
-
-
-
-